- Home
- IDR vs ENTA Comparison
IDR vs ENTA Comparison
Compare IDR & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- ENTA
- Stock Information
- Founded
- IDR 1996
- ENTA 1995
- Country
- IDR United States
- ENTA United States
- Employees
- IDR N/A
- ENTA N/A
- Industry
- IDR Precious Metals
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- ENTA Health Care
- Exchange
- IDR Nasdaq
- ENTA Nasdaq
- Market Cap
- IDR 180.8M
- ENTA 164.6M
- IPO Year
- IDR N/A
- ENTA 2013
- Fundamental
- Price
- IDR $19.90
- ENTA $7.40
- Analyst Decision
- IDR Strong Buy
- ENTA Buy
- Analyst Count
- IDR 1
- ENTA 4
- Target Price
- IDR $17.50
- ENTA $18.00
- AVG Volume (30 Days)
- IDR 628.1K
- ENTA 174.8K
- Earning Date
- IDR 08-05-2025
- ENTA 08-04-2025
- Dividend Yield
- IDR N/A
- ENTA N/A
- EPS Growth
- IDR 144.40
- ENTA N/A
- EPS
- IDR 0.62
- ENTA N/A
- Revenue
- IDR $27,144,971.00
- ENTA $64,462,999.00
- Revenue This Year
- IDR $9.76
- ENTA N/A
- Revenue Next Year
- IDR N/A
- ENTA $2.75
- P/E Ratio
- IDR $32.09
- ENTA N/A
- Revenue Growth
- IDR 67.42
- ENTA N/A
- 52 Week Low
- IDR $9.58
- ENTA $4.09
- 52 Week High
- IDR $21.96
- ENTA $15.92
- Technical
- Relative Strength Index (RSI)
- IDR 70.28
- ENTA 52.23
- Support Level
- IDR $19.13
- ENTA $7.24
- Resistance Level
- IDR $21.96
- ENTA $8.11
- Average True Range (ATR)
- IDR 1.27
- ENTA 0.50
- MACD
- IDR 0.30
- ENTA -0.01
- Stochastic Oscillator
- IDR 78.44
- ENTA 57.61
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.